Kalaris Therapeutics Announces Additional Data From Its Phase 1A Trial Of TH103 In Neovascular Age-Related Macular Degeneration; Additional Patients Showed Improvements In Vision And Retinal Anatomy

Loading news article.

Kalaris Therapeutics Announces Additional Data From Its Phase 1A Trial Of TH103 In Neovascular Age-Related Macular Degeneration; Additional Patients Showed Improvements In Vision And Retinal Anatomy | WAPE

Kalaris Therapeutics Announces Additional Data From Its Phase 1A Trial Of TH103 In Neovascular Age-Related Macular Degeneration; Additional Patients Showed Improvements In Vision And Retinal Anatomy

Article summary

Related companies

Comments —